Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
pmid:21205027 8
This has really curbed my desire for all the bad things I was eating
Clinical Profile of Exenatide To understand subsequent innovations, its helpful to summarize exenatides clinical profile (as the first GLP-1 RA): Efficacy: In trials, twice-daily exenatide (10 g BID) typically reduced HbAc by approximately 0.8%1.0% more than placebo by 30 weeks ( [61] ) ( [101] )
Despite their clinical relevance, these conventional approaches often suffer from low long-term adherence due to barriers such as palatability restrictions, environmental influences, and behavioral fatigue (2931)
28 (7-8):753-6 Yasushi Honda, Takaomi Kessoku, Yoshio Sumida, Takashi Kobayashi, Takayuki Kato, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Koshi Kataoka, Masataka Taguri, Takeharu Yamanaka, Yuya Seko, Saiyu Tanaka, Satoru Saito, Masafumi Ono, Satoshi Oeda, Yuichiro Eguchi, Wataru Aoi, Kenji Sato, Yoshito Itoh, and Atsushi Nakajima - Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study - BMC Gastroenterol
